Tarsus Pharmaceuticals: Q4 Results Highlight Xdemvy Blockbuster Potential

2026-02-24 13:47:24 ET

I have covered Tarsus Pharmaceuticals ( TARS ) several times, highlighting the company as a Buy due to the robust growth of Xdemvy. Since my first article one year ago, the stock has risen from $47 to $75, a 60% gain that outpaced the S&P 500. In 2026, Tarsus has struggled as investors fretted about AI spending, substituting dividend-paying stocks in place of growth-oriented stocks. In this case, these fears seem unfounded, as shown by Tarsus' Q4 2025 results and 2026 guidance, demonstrating that the growth thesis has only strengthened....

Read the full article on Seeking Alpha

For further details see: